Alnylam: Positive Results from Phase 2 Study of Treatment of IgA Nephropathy

 -Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo -

- Consistent Proteinuria Reduction Seen with Secondary Endpoints -
- Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy -

 https://www.biospace.com/article/releases/alnylam-reports-positive-results-from-phase-2-study-of-investigational-cemdisiran-for-the-treatment-of-iga-nephropathy/